MedaSystems
Makes it easy for life science companies and health care providers to collaborate on requests for access to experimental therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Seed | |
| Total Funding | 000k | ||
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 80 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
MedaSystems is a forward-thinking startup focused on simplifying the process of accessing investigational medicines for patients and healthcare providers. The company operates in the life sciences sector, specifically targeting pharmaceutical manufacturers and biotechnology firms. MedaSystems offers a software platform that helps these companies manage and streamline requests for investigational drugs, which are medicines still under study and not yet approved for general use.
The primary clients of MedaSystems are pharmaceutical manufacturers and biotechnology companies. These clients use MedaSystems' platform to handle various types of access programs, including Expanded Access (providing investigational drugs to patients outside of clinical trials), Post Trial Access (continuing treatment after a trial ends), and managing proposals for new clinical studies. By using MedaSystems, these companies can collaborate in real-time with healthcare providers, make faster approval decisions, and reduce repetitive administrative tasks.
MedaSystems' business model revolves around providing its software as a service (SaaS). This means clients subscribe to use the platform, paying a recurring fee for access and support. The company generates revenue through these subscription fees, which can vary based on the level of service and number of users.
One of the key benefits of MedaSystems' platform is its ability to significantly cut down response times for Expanded Access requests. For instance, a biotechnology company using MedaSystems was able to reduce their response times by 75%, enabling faster and more efficient communication with physicians and patients.
In summary, MedaSystems is revolutionizing the way investigational medicines are accessed by reducing administrative burdens and improving communication between pharmaceutical companies and healthcare providers.
Keywords: investigational medicines, pharmaceutical manufacturers, biotechnology, Expanded Access, Post Trial Access, clinical studies, SaaS, workflow management, healthcare providers, life sciences.